期刊
DRUG DISCOVERY TODAY
卷 26, 期 7, 页码 1591-1601出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.03.018
关键词
Neuromyelitis optica; NMOSD; Interleukin-6; Monoclonal antibody; Disease-modifying therapy; Neonatal pathway; Aquaporin antibody
资金
- Roche, Austria
Neuromyelitis optica spectrum disorder (NMOSD) is a rare disease of the central nervous system (CNS) with poor outcomes, and recent clinical trials have shown therapeutic benefits of IL-6 blockade. Tocilizumab and satralizumab are widely used IL-6 receptor inhibitors, successful in extending the half-life of antibodies and highlighting the potential therapeutic benefits of the emerging technology.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare disease of the central nervous system (CNS) that is associated with poor outcomes for patients. Until recently, when complement inhibitors were approved, there was no approved therapy. Most recently, clinical trials of interleukin-6 (IL-6) blockade showed a therapeutic benefit for NMOSD. In this review, we introduce the immunological basis of IL-6 blockade in NMOSD and summarize current knowledge about the clinical use of the IL-6 receptor inhibitors tocilizumab and satralizumab. The aim of extending the half-life of monoclonal antibodies (mAbs) has been actualized by successful clinical translation for Satralizumab, achieved via the neonatal Fc receptor (FcRn) pathway. The basic principles of FcRn are highlighted in this review together with the potential therapeutic benefits of this emerging technology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据